Clairity Raises $43 Million in Series B to Launch AI Platform for Breast Cancer Risk Prediction.
PRIVATENov 13, 2025
Amount Raised
$43 Million
Round Type
Series B
BostonHealthcareHealth Care
Investors
Breast Cancer Research FoundationACE Global EquitySanté Ventures
Description
Clairity, Inc. has closed a $43 million Series B financing to commercialize its FDA-authorized AI platform for predicting breast cancer risk. The round was led by ACE Global Equity and Santé Ventures, with support from the Breast Cancer Research Foundation. The funding will help accelerate U.S
Who to call at Clairity, and when
A new round usually means Clairity is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Clairity raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Clairity, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Clairity. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Clairity
Location
361 Newbury Street, Suite 402
Boston, Massachusetts, United States
About
Clairity is an AI-powered precision health company transforming medical imaging into a predictive tool for early risk assessment. Its flagship product, Clairity Breast, is the first FDA-cleared platform to estimate a woman’s five-year breast cancer risk directly from a routine mammogram. By shifting care from detection to prevention, Clairity empowers health systems, radiologists, and women to act earlier, save lives, and lower the overall cost of cancer care.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Clairity raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BostonHealthcareHealth Care